Genomic Valley Biotech Limited reports Rs 1.98 lakh September loss

Genomic Valley Biotech Limited reported a Rs 1.98 lakh net loss for the quarter ended September 30, 2026, as total income from operations was nil. The standalone unaudited result reversed net profits of Rs 1.46 lakh in the June 2026 quarter and Rs 0.33 lakh in the September 2025 quarter.

What did Genomic Valley Biotech report for September 2026?

Genomic Valley Biotech reported a net loss after tax of Rs 1.98 lakh for the quarter ended September 30, 2026. Its loss before tax and exceptional or extraordinary items was also Rs 1.98 lakh, while total comprehensive income was negative Rs 1.98 lakh for the same three-month period.

The September 2026 result marked a reversal from net profit after tax of Rs 1.46 lakh in the preceding three months ended June 30, 2026, and Rs 0.33 lakh in the corresponding quarter ended September 30, 2025. The published extract classified all three quarterly sets of figures as standalone and unaudited.

Why did Genomic Valley Biotech move from profit to loss?

Genomic Valley Biotech reported nil total income from operations in the September 2026 quarter, compared with Rs 3.80 lakh in the June 2026 quarter and Rs 9.00 lakh a year earlier. The newspaper extract does not identify the operating activities or revenue streams behind the change to nil income.

The loss followed two profitable comparison quarters, with profit after tax changing from Rs 1.46 lakh in June 2026 to a Rs 1.98 lakh loss in September 2026. Against September 2025, the company moved from a Rs 0.33 lakh profit to a loss, but the extract does not provide operating-expense, finance-cost or tax line items to explain the movement.

The same Rs 1.98 lakh negative figure was reported before tax, after tax and as total comprehensive income for September 2026. It was also unchanged before and after exceptional or extraordinary items, although the extract does not specify the treatment of tax or whether any exceptional or extraordinary items arose in the quarter.

How does the September 2026 quarter compare with 2025-26?

Genomic Valley Biotech's September 2026 loss contrasts with a Rs 3.03 lakh net profit after tax for the year ended March 31, 2026. The audited full-year result reported total income from operations of Rs 26.75 lakh, while the September 2026 quarterly result reported nil operating income.

Profit before tax and exceptional or extraordinary items was Rs 4.00 lakh for the year ended March 31, 2026, compared with a Rs 1.98 lakh loss on that measure for the September 2026 quarter. These are not like-for-like periods because the annual result covers 12 months and the September result covers three months.

The annual figures show that Genomic Valley Biotech recorded positive operating income and profit in 2025-26, whereas the September 2026 quarter recorded neither operating income nor profit. The filing also says prior-period figures were regrouped or reclassified wherever necessary, without quantifying any such changes.

What happened to Genomic Valley Biotech's earnings per share and share capital?

Genomic Valley Biotech reported basic and diluted loss per share of Rs 0.06 for the quarter ended September 30, 2026. This compared with earnings per share of Rs 0.05 in the June 2026 quarter, Rs 0.01 in the September 2025 quarter and Rs 0.10 for the year ended March 31, 2026.

The earnings-per-share disclosure covers continuing and discontinued operations and is based on equity shares with a face value of Rs 10 each. Equity share capital was unchanged at Rs 30.545 lakh in each of the September 2026, June 2026 and September 2025 columns, so the reported per-share change occurred without a disclosed change in capital across those quarters.

When were Genomic Valley Biotech's results reviewed and approved?

Genomic Valley Biotech said its board took the September 2026 results on record on October 30, 2026, after an audit committee review. The company also said its statutory auditor carried out a limited review of the financial results for the period ended September 30, 2026.

The November 2, 2026 filing submitted newspaper advertisements under Regulation 47 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. It describes the published numbers as an extract of detailed quarterly results filed under Regulation 33 and says the full format is available through the stock exchange and company websites.

Conclusion

Genomic Valley Biotech's September 2026 quarter recorded a Rs 1.98 lakh loss after operating income declined to nil, reversing profits reported in both the Rs 1.46 lakh June 2026 quarter and the Rs 0.33 lakh September 2025 quarter. The reported loss was identical before tax, after tax and in total comprehensive income, while loss per share was Rs 0.06.

What to watch next is the detailed quarterly-results format that Genomic Valley Biotech says is available through the stock exchange and its website. That format may address matters not quantified in the newspaper extract, including the components of expenses, tax treatment and the reason operating income was nil in the quarter ended September 30, 2026.